Cationic emulsions (from physicochemical characterization to application in ocular delivery)

In this thesis, we have studied cationic emulsions containing oleylamine (OA) which are developed for ocular delivery. In a first study we focused in the physicochemical aspects of the droplet surface, studying the OA distribution whithin the droplet and finding a basic surface pH. We developed then an analytical method which allowed us to evaluate the impact of this alkaline surface on phospholipids hydrolysis. Using this and other techniques, we evaluated the stability of the emulsions during accelerated storage conditions. Finally, the emulsions successfully delivered cyclosporine A when injected intravitreally in an animal model of ocular inflammation.Dans cette thèse, nous avons étudié les émulsions cationiques contenant de l'oleylamine (OA), développées pour l'administration oculaire. Dans une première étude nous nous sommes centrés sur les caractéristiques physico-chimiques de la surface de la gouttelette en étudiant la distribution de l'OA dans la gouttelette et en mesurant le pH de surface. Une méthode analytique a été développée pour nous permettre d' évaluer l'impact de l'alcalinité de surface sur l'hydrolyse des phospholipides. Grâce à cette méthode et d'autres techniques, nous avons évalué la stabilité des émulsions conservées dans des conditions de conservation accélérées. Finalement, les émulsions ont permis d'administrer de la CsA par injection intraoculaire dans un modèle d'inflammation oculaire animal.CHATENAY M.-PARIS 11-BU Pharma. (920192101) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

Impression cytology evaluated by flow cytometry and viewed after cytospin centrifugation

<p><b>Copyright information:</b></p><p>Taken from "Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits"</p><p></p><p>Molecular Vision 2008;14():204-216.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2254971.</p><p></p> Percentages of RLA-DR- () and TNFR1- () positive cells after multiple instillations of PBS, BAK Sol, BAK Em, CKC Sol, CKC Em is displayed. The astersisk indicates that

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and safety of 14C-omacetaxine in patients with solid tumors. Methods The study comprised a 7-days pharmacokinetic assessment followed by a treatment period of ≤ six 28-days cycles. A single subcutaneous dose of 1.25 mg/m2 14C-omacetaxine was administered to six patients. Blood, urine, and feces were collected through 168 h or until radioactivity excreted within 24 h was <1 % of the dose. Total radioactivity (TRA) was measured in all matrices and concentrations of omacetaxine, 4′-desmethylhomoharringtonine (4′-DMHHT), and cephalotaxine were measured in plasma and urine. For each treatment cycle, patients received 1.25 mg/m2 omacetaxine twice daily for 7 days. Results Mean TRA recovered was approximately 81 % of the dose, with approximately half of the radioactivity recovered in feces and half in urine. Approximately 20 % of the dose was excreted unchanged in urine; cephalotaxine (0.4 % of dose) and 4′ DMHHT (9 %) were also present. Plasma concentrations of TRA were higher than the sum of omacetaxine and known metabolites, suggesting the presence of other 14C-omacetaxine-derived compounds. Fatigue and anemia were common, consistent with the known toxicity profile of omacetaxine. Conclusion Renal and hepatic processes contribute to the elimination of 14C-omacetaxine-derived radioactivity in cancer patients. In addition to omacetaxine and its known metabolites, other 14C-omacetaxine-derived materials appear to be present in plasma and urine. Omacetaxine was adequately tolerated, with no new safety signals